Mustafa Khasraw
A5004781307- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Epigenetics and DNA Methylation
- CAR-T cell therapy research
- Neuroblastoma Research and Treatments
- Cancer Research and Treatments
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- ATP Synthase and ATPases Research
- PARP inhibition in cancer therapy
- Heat shock proteins research
- Mitochondrial Function and Pathology
- Cancer Treatment and Pharmacology
- Cancer, Hypoxia, and Metabolism
- Colorectal Cancer Treatments and Studies
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
Duke University Hospital
2020-2025
Duke Medical Center
2020-2025
Duke University
2020-2025
Duke Cancer Institute
2021-2025
The Royal Melbourne Hospital
2012-2024
Duke University Health System
2024
The University of Sydney
2014-2023
National Health and Medical Research Council
2009-2023
Royal North Shore Hospital
2009-2022
Hudson Institute
2022
•TMB-H failed to predict improved or clinically relevant response ICB in all cancer types.•Cancer types where TMB-H does not generally show no relationship between tumor neoantigen load and CD8 T-cell infiltration.•Further studies should be carried out before application of as a biomarker for types. BackgroundHigh mutation burden (TMB-H) has been proposed predictive immune checkpoint blockade (ICB), largely due the potential mutations generate immunogenic neoantigens. Despite recent...
Abstract Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-1 (PD-1) and PD-L1, have transformed the management of many cancers. However, majority patients primary or acquired resistance to these immunotherapies. There is a significant unmet need for predictive biomarkers can reliably identify who derive clinically meaningful response from PD-1/PD-L1 blockade. High tumor mutational burden (TMB-H) has shown promise as biomarker in lung cancer, but...
Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that tumors harboring an unmethylated MGMT promoter derive minimal benefit. The aim this open-label, phase III CheckMate 498 study was evaluate the efficacy nivolumab (NIVO) + RT compared TMZ newly diagnosed GBM promoter.Patients were randomized 1:1 standard (60 Gy) NIVO (240 mg every 2 weeks for eight cycles, then 480 4 weeks) or (75 mg/m2...
Background: PET scans using FDG and somatostatin receptor imaging agents have both been used to study neuroendocrine tumours.Most reports documented the sensitivity specificity of each radiopharmaceutical independently, even suggested superiority one over other for different grades disease.Aim: The aim this work was develop a grading scheme that describes joint results in staging subjects with tumours single combined parameter.The has developed is referred as NETPET grade.Methods: This...
The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8
Spinal ependymal tumors form a histologically and molecularly heterogeneous group of with generally good prognosis. However, their treatment can be challenging if infiltration the spinal cord or dissemination throughout central nervous system (CNS) occurs and, in these cases, clinical outcome remains poor. Here, we describe new relatively rare subgroup identified using DNA methylation profiling that is distinct from other molecular subgroups ependymoma. Copy number variation plots derived...
Expression of programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) across glioma grades is undocumented, and their interactions with commonly expressed genetic epigenetic alterations are undefined but nonetheless highly relevant to combinatorial treatments. Patients CNS malignancies were profiled by Caris Life Sciences from 2009 2016. Immunohistochemistry findings for PD-1 on tumor-infiltrating lymphocytes (TIL) PD-L1 tumor cells available 347 cases. Next-generation sequencing,...
<h3>Objectives</h3> Using the prediction of cancer outcome as a model, we have tested hypothesis that through analysing routinely collected digital data contained in an electronic administrative record (EAR), using machine-learning techniques, could enhance conventional methods predicting clinical outcomes. <h3>Setting</h3> A regional centre Australia. <h3>Participants</h3> Disease-specific from purpose-built registry (Evaluation Cancer Outcomes (ECO)) 869 patients were used to predict...
Abstract Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits 10–20% of patients. Here we perform genomic analysis tumor tissue from WHO grade IV patients acquired prior to intervention. We report that very low mutation burden is associated with longer after recombinant polio virotherapy or immune checkpoint blockade A relationship between and not observed cohorts naïve newly diagnosed Transcriptomic analyses reveal an inverse enrichment...
Understanding the molecular basis of drug resistance and utilising this information to overcome chemoresistance remains a key challenge in oncology.Here we report that survivin, protein implicated resistance, is overexpressed cancer stem cell pool doxorubicin-resistant breast cells.Moreover, by an active targeting system consisting RNA aptamer targeted against epithelial adhesion molecule Dicer substrate survivin siRNA, could deliver high dose siRNA cells xenograft tumours.Importantly,...
Abstract Background Temozolomide offers minimal benefit in patients with glioblastoma unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies. This study evaluated whether veliparib, a brain-penetrant poly(ADP-ribose) polymerase (PARP) inhibitor, acts synergistically radiation and temozolomide. Methods VERTU was multicenter 2:1 randomized phase II trial newly diagnosed MGMT-unmethylated promotor status. The experimental arm consisted of...